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Introduction {#sec1}
============

The diversity of human immunoglobulin (Ig) gene repertoire is shaped by antibody diversification processes occurring at different stages of B lymphocytes development ([@bib29], [@bib51]). Class switch recombination (CSR) is a DNA rearrangement reaction occurring in mature B lymphocytes, which replaces the constant portion of the IgM heavy chain with one of the alternative isotypes (IgG, IgA, or IgE). As a consequence, this process alters the Ig effector function without affecting its antigen specificity ([@bib15], [@bib51]). CSR is crucial to the establishment of a proper immune response because it enhances the capability of antigen-specific Igs to effectively dispose of the pathogens ([@bib31]).

The *Igh* locus of mature B lymphocytes spans more than 250 kb and comprises a rearranged VDJ region and a series of exon sets encoding the different constant (C) regions (Cμ, Cγ3, Cγ1, Cγ2b, Cγ2a, Cε, and Cα in mice), which define the Ig isotypes. CSR occurs through a deletional recombination event that replaces the μ constant gene of the Ig heavy chain with one of the several downstream constant regions. The reaction is initiated in G1 by the B cell-specific enzyme activation-induced deaminase (AID), which targets highly repetitive stretches of DNA preceding each constant region (switch \[S\] regions) in a transcription-dependent manner ([@bib16], [@bib23], [@bib53], [@bib60], [@bib64]). AID activity ultimately leads to the formation of DNA double-strand breaks (DSBs) ([@bib4], [@bib51]). During CSR, breaks at the donor Sμ region and one of the downstream acceptor switch regions are repaired by components of the non-homologous end joining (NHEJ) DSB repair pathway. NHEJ directly ligates CSR DSBs after minimal DNA end processing, resulting in deletion of the intervening sequence and expression of the newly switched heavy chain ([@bib13], [@bib14], [@bib22], [@bib32], [@bib49], [@bib50], [@bib56], [@bib61], [@bib75], [@bib80]).

Productive joining of distal breaks in donor and acceptor switch regions represents only one of the possible outcomes of AID-induced DSB repair. Switch region breaks can also be internally re-joined, leading to unproductive intra-switch recombination ([@bib1], [@bib8], [@bib28], [@bib38], [@bib41], [@bib61], [@bib62], [@bib79]). Given the repetitive nature of the switch regions, intra-S recombination events are favored by limited resection, which, combined with the intra-S break proxymity, skews repair toward the preferential use of the exposed microhomologies (microhomology-mediated end joining \[MMEJ\]) ([@bib3], [@bib7], [@bib30], [@bib80], [@bib81]).

The balance between NHEJ-mediated CSR and MMEJ-intra-S recombination is controlled by the DNA end resection inhibitory function of 53BP1 ([@bib5], [@bib6], [@bib7], [@bib50], [@bib63], [@bib75]), a DSB repair protein that has emerged as a key regulator of DNA end processing ([@bib58], [@bib85]). 53BP1 binds damaged chromatin and recruits its phospho-dependent interactor Rif1, which protects DSB ends against processing by the DNA resection-promoting factor CtIP ([@bib14], [@bib22], [@bib32], [@bib34], [@bib86]). This function is mediated by the downstream REV7-SHLD1-SHLD2-SHLD3 (shieldin) and CTC1-STN1-TEN1 (CST) complexes, which localize to sites of DNA damage and counteract DSB end resection ([@bib21], [@bib35], [@bib37], [@bib39], [@bib52], [@bib55], [@bib71]). In addition to CSR, the DNA end resection inhibitory function of 53BP1-RIF1-shieldin promotes fusion of telomeres that lack shelterin protection, and end joining of unrepaired chromatid breaks into radial chromosomes in Brca1-deficient cells ([@bib11], [@bib14], [@bib21], [@bib25], [@bib37], [@bib39], [@bib52], [@bib67], [@bib86]). These aberrant DNA repair reactions require 53BP1-dependent DSB end mobility in addition to its DNA end protection function ([@bib25], [@bib48]).

Protection of AID-induced DSBs against resection is thought to play a central role during CSR. However, the actual extent to which 53BP1-Rif1-dependent repression of DNA resection is required for CSR is not known. Here, we dissected the contribution of the different functions of 53BP1 to CSR. We show that CSR is only marginally dependent on 53BP1-Rif1-mediated inhibition of DNA end processing, whereas the formation of higher order 53BP1 oligomers is crucial for the reaction. Furthermore, CSR does not require the DSB-induced chromatin mobility function of 53BP1. This sets CSR apart from the other DNA repair reactions mediated by 53BP1, fusion of deprotected telomeres and formation of radial chromosomes.

Results {#sec2}
=======

Disruption of 53BP1 Higher Order Oligomerization Abrogates CSR {#sec2.1}
--------------------------------------------------------------

Deletion of amino acids 1231--1270 of human 53BP1 interferes with 53BP1 oligomerization and abrogates its ability to rescue CSR in 53BP1-deficient B lymphocytes ([@bib6], [@bib76], [@bib83]). This amino acid stretch contains predicted secondary structure elements ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A), suggesting the presence of a folded oligomerization domain (OD) in this region. To dissect how 53BP1 multimerization supports CSR, we fused the peptide sequence encompassing amino acids 1233--1288 to the maltose-binding protein (MBP) ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C) and assessed the oligomerization status of the fusion protein by gel filtration analysis coupled to right-angle light scattering (RALS). In these experiments, MBP-OD eluted as a tetramer ([Figure 1](#fig1){ref-type="fig"}B; MBP-OD^WT^). Mutation of the evolutionarily conserved residue D1256 led to a dimeric species, whereas the deletion of the OD core (amino acids 1254--1258) rendered the protein monomeric ([Figure 1](#fig1){ref-type="fig"}B). In agreement with these data, co-immunoprecipitation analysis of differentially tagged 53BP1 constructs showed that deletion of the OD core destabilized 53BP1 oligomerization more severely than the D1256A mutation ([Figure 1](#fig1){ref-type="fig"}C). These findings indicate that the OD acts as an independent tetramerization module, and D1256 is part of an interface that mediates dimerization of 53BP1 dimers. Notably, this analysis provided us with a tool to dissect the role of 53BP1 dimerization and tetramerization for CSR and the regulation of DNA end resection.Figure 1Disruption of 53BP1 Higher Order Oligomerization Abrogates CSR without Affecting DSB End Protection(A) Schematic representation of 53BP1 protein domains and OD mutants. LC8, LC8 (8 kDa light chain dynein)-binding motif; OD, oligomerization domain; Tudor, Tudor domain; UDR, ubiquitylation-dependent recruitment motif; ΔBRCT, BRCA1 C terminus domains-truncated.(B) Gel filtration coupled to right-angle light scattering (RALS) analysis of the OD constructs fused to N-terminal MBP. UV absorbance is shown in red-blue-green-brown and refers to the left y axis, whereas the molecular mass of the constructs as deduced by RALS is shown in the corresponding brighter colors and refers to the right y axis. Results are representative of two independent experiments. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.(C) Western blot (WB) analysis of anti-HA immunoprecipitates from irradiated (20 Gy; 1 h recovery time) BOSC23 cells transfected with the indicated 53BP1-3xFlag/-3xHA constructs. Numbers underneath each lane indicate relative quantification of oligomutant versus WT 53BP1-3xFlag proteins in anti-HA immunoprecipitates (53BP1^WT^-3xFlag set to 1). Results are representative of two independent experiments. EV, empty vector.(D) Top: representative flow cytometry plots measuring CSR to IgG1 in *WT* and *53bp1*^*−/−*^ splenocytes transduced with the indicated constructs. Numbers in the plots refer to the percentage of switched cells (IgG1^+^ cells). Bottom: summary dot plot for four independent experiments. CSR efficiencies within each experiment were normalized to the CSR value of 53BP1^WT^-reconstituted cells, which was set to 100%.(E) Representative WB analysis of *53bp1*^*−/−*^ B lymphocytes reconstituted with the indicated 53BP1 viral constructs.(F and G) Automated IRIF quantification of immunofluorescent staining for 53BP1 (F) and Rif1 (G) in irradiated (10 Gy; 2 h recovery time) *53bp1*^*−/−*^ iMEFs reconstituted with the indicated constructs. The top graph within each panel shows a representative experiment, and the bottom graph summarizes the mean values of three experiments performed on three independent sets of reconstituted cell lines. Each symbol in the top graph represents a single cell, and the number of scored cells was ≥200 per sample. The mean is indicated. Either 53BP1^mTudor^ or 53BP1^mUDR^ was included in parallel to EV as an additional control in the individual repeats. The representative experiments in (F) and (G), top graphs, used 53BP1^mTudor^. See also [Figure S2](#mmc1){ref-type="supplementary-material"}B for representative immunofluorescent staining images.(H) Schematic representation of the BrdU assay for DNA end resection. BrdU treated cells were analyzed for BrdU content under native (not denatured) conditions to estimate resection levels following NCS treatment. Adapted from ([@bib70]).(I) Representative BrdU fluorescence-activated cell sorting (FACS) plots showing levels of resection in NCS-treated *53bp1*^*−/−*^ iMEF reconstituted with the indicated constructs.(J) Summary graph showing quantification of the BrdU FACS data represented in (I) for four experiments performed on three independent sets of reconstituted cell lines. Numbers above each bar indicate the fold mean BrdU intensity over WT, which was set to 1.Significance in (D), (F), (G), and (J) was calculated using the Mann-Whitney U test, and error bars represent SD. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.001, and ^∗∗∗∗^p ≤ 0.0001; ns, not significant. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

To assess how the differential assembly of 53BP1 influenced its ability to support CSR, we compared the capability of 53BP1^ΔOligo^, 53BP1^ΔCore^, and 53BP1^D1256A^ to rescue CSR in *53bp1*^*−/−*^ B cells. We used primary cultures of splenocytes and monitored CSR *ex vivo* to IgG1 in response to stimulation with LPS and IL-4. As expected, *53bp1*^*−/−*^ B cells exhibited 10-fold lower levels of CSR compared with wild-type (WT) cells, and reconstitution with 53BP1^WT^ efficiently rescued CSR ([Figures 1](#fig1){ref-type="fig"}D and 1E). On the contrary, none of the OD mutants significantly elevated CSR efficiency above the levels of the empty vector (EV) control or of a 53BP1 mutant that cannot associate with chromatin (53BP1^mTudor^) ([Figure 1](#fig1){ref-type="fig"}D). We concluded that the integrity of 53BP1 higher order oligomers is a pre-requisite for CSR.

Oligomerization-Impaired 53BP1 Is Able to Counteract DSB End Resection {#sec2.2}
----------------------------------------------------------------------

In undamaged cells, 53BP1 associates with its direct binding partner Tudor interacting repair regulator (TIRR), which binds to 53BP1 tandem Tudor domain and masks the H4K20me2 binding surface ([@bib10], [@bib17], [@bib27], [@bib73], [@bib84]). Upon DNA damage, the 53BP1-TIRR complex dissociates ([@bib27], [@bib84]), and 53BP1 is recruited to the damaged chromatin via the direct bivalent interaction of its Tudor domain and ubiquitination-dependent recruitment (UDR) motif with H4K20me2 and H2AK15ub histone modifications, respectively ([@bib9], [@bib36], [@bib42], [@bib66]). 53BP1 engages the modified nucleosomes as a dimer in a pincer-like binding mode, and this interaction arrangement has been postulated to enable its DNA end resection inhibitory activity ([@bib36], [@bib78]).

To assess to what extent impaired oligomerization of 53BP1 affects DNA end protection against resection, we first examined the ability of 53BP1 OD mutants to recruit Rif1 to sites of ionizing radiation (IR)-induced DNA damage. To this end, we reconstituted *53bp1*^*−/−*^ immortalized mouse embryonic fibroblasts (iMEFs) with 53BP1^WT^ and OD mutant constructs ([Figure S2](#mmc1){ref-type="supplementary-material"}A) and monitored 53BP1 and Rif1 irradiation-induced foci (IRIF) formation by high-throughput microscopy quantification. As expected, the constitutive association of 53BP1 with chromatin (53BP1^mTudor^) and its DNA damage-induced recruitment (53BP1^mUDR^) were necessary for efficient 53BP1 IRIF formation ([Figures 1](#fig1){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}B). In contrast, mutations or deletions disrupting the OD assembly or deletion of the entire OD only partially affected 53BP1 localization to DSBs ([Figures 1](#fig1){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}B). Furthermore, the OD mutants were either as proficient as 53BP1^WT^ (53BP1^D1256A^) or only minimally affected (53BP1^ΔOligo^ and 53BP1^ΔCore^) in recruiting Rif1 to damaged chromatin ([Figures 1](#fig1){ref-type="fig"}G and [S2](#mmc1){ref-type="supplementary-material"}B). This indicates that the reduced capability of 53BP1 to localize to sites of DNA damage does not significantly interfere with its ability to recruit Rif1.

Next, we tested the capability of these mutants to repress resection of DNA breaks induced by the radiomimetic drug neocarzinostatin (NCS). To this end, we used the 5-bromo-2′-deoxyuridine (BrdU) DNA end resection assay, which measures the levels of BrdU exposed by DNA processing as a quantitative readout for DNA end resection ([Figure 1](#fig1){ref-type="fig"}H). In agreement with the well-established role of 53BP1 in the inhibition of DNA end resection, cells transduced with EVor the 53BP1^mTudor^ mutant displayed a high BrdU signal ([Figures 1](#fig1){ref-type="fig"}I and 1J), which is indicative of extensive DNA processing. Reconstitution with 53BP1^WT^ rescued the phenotype ([Figures 1](#fig1){ref-type="fig"}I and 1J). OD mutant-expressing iMEFs exhibited only slightly increased BrdU levels compared with 53BP1^WT^ ([Figures 1](#fig1){ref-type="fig"}I and 1J), indicating that assembly via the OD does not have a major impact on 53BP1-mediated inhibition of DNA end processing.

To assess for DNA end resection at the single nucleotide level, we used CRISPR/Cas9 nuclease and AID as DNA break-inducing source in CH12 cells. CH12 is a murine B cell lymphoma line that expresses AID and undergoes efficient CSR to IgA following cytokine stimulation ([@bib54]). We used CRISPR-Cas9 somatic gene targeting to generate a CH12 cell line that harbored a deletion in the *53bp1* locus encompassing the OD core (*53bp1*^*Δ6*^ CH12) ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). This cell line recapitulated the severe CSR deficiency ([Figure S3](#mmc1){ref-type="supplementary-material"}C) of oligomutant-reconstituted primary B cells ([Figure 1](#fig1){ref-type="fig"}D). We first monitored processing of Cas9-induced breaks at the *Rosa26* locus using a well-established DSB end resection assay (Rosa26-ERA; [Figure S3](#mmc1){ref-type="supplementary-material"}D). *53bp1*^*Δ6*^ CH12 cells were as proficient as WT cells in preventing resection of CRISPR-Cas9-induced DSBs ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Next, we compared the frequency and length of microhomologies (MHs) at Sμ-Sα junctions in cells activated to undergo CSR. 53BP1 deficiency results in CSR junctions skewed toward the preferential use of MHs as a consequence of increased resection of AID-induced breaks ([@bib57]). In agreement with this observation, *53bp1*^*−/−*^ CH12 cells displayed the expected bias toward MH-dependent end joining, with twice as many junctions as in WT cells presenting ≥3 bp MH ([Figure S3](#mmc1){ref-type="supplementary-material"}E; [Table S1](#mmc1){ref-type="supplementary-material"}). In contrast, Sμ-Sα ligation events with ≥3 bp MH were only modestly increased in *53bp1*^*Δ6*^ cells ([Figure S3](#mmc1){ref-type="supplementary-material"}E; [Table S1](#mmc1){ref-type="supplementary-material"}). In line with these results, *53bp1*^*Δ6*^ CH12 cells accumulated reduced levels of the single-stranded binding protein complex RPA at donor and acceptor switch regions compared with *53bp1*^*−/−*^ CH12 ([Figure S3](#mmc1){ref-type="supplementary-material"}F).

Altogether, these findings indicate that the assembly of 53BP1 higher order oligomers via the OD is largely dispensable for inhibition of DSB resection yet essential for CSR.

DSB End Protection-Deficient B Lymphocytes Undergo Robust CSR {#sec2.3}
-------------------------------------------------------------

Following the generation of AID-induced breaks, 53BP1 recruits Rif1 to protect switch region breaks against resection ([@bib14], [@bib22], [@bib32]). Given the severe defect of the OD core mutants to support CSR despite minimally affected DNA end protection capabilities, we next examined to what extent the regulation of DNA end resection contributed to 53BP1's role in CSR.

53BP1's ability to inhibit DNA end resection is dependent on phosphorylation of the N-terminal SQ/TQ sites, as a mutant bearing alanine substitutions of all 28 N-terminal motifs (53BP1^28A^; [Figure 2](#fig2){ref-type="fig"}A) cannot interact with Rif1 and support CSR despite being normally recruited to sites of DNA damage ([@bib6], [@bib14], [@bib22], [@bib32]). However, 53BP1^28A^ is also impaired in DNA damage-induced chromatin mobility, a Rif1-independent function of 53BP1 that is required for both telomere fusion and radial formation ([@bib25], [@bib47], [@bib48], [@bib86]). To assess the specific contribution of Rif1-mediated inhibition of DSB resection to CSR, we generated 53BP1 mutants that harbored alanine substitutions in the SQ/TQ sites within the N-terminal DNA end protection domain (Pro domain; [Figure 2](#fig2){ref-type="fig"}A) but retained all SQ/TQ sites in the mobility domain (Mob domain; [Figure 2](#fig2){ref-type="fig"}A). This yielded 53BP1^ΔPro^, which contained mutations in the first 15 N-terminal SQ/TQ sites, and 53BP1^ΔRif1^, which preserved the SQ sites in the PTIP-binding region ([Figure 2](#fig2){ref-type="fig"}A).Figure 2Inactivation of 53BP1 SQ/TQ Sites T302 to S625 Is Sufficient to Abolish Rif1-Dependent Inhibition of DNA End Resection(A) Top: schematic representation of 53BP1 protein with the position of the 28 N-terminal SQ/TQ motifs indicated as black circles. Bottom: schematic representation of the 53BP1 phospho mutants with S/TQ sites indicated as black circles and S/TQ-to-AQ substitutions marked in light gray. Pro, DNA end protection SQ/TQ set; Mob, DNA mobility SQ/TQ set.(B and C) Automated IRIF quantification of immunofluorescent staining for 53BP1 (B) and Rif1 (C) in irradiated (10 Gy; 2 h recovery time) *53bp1*^*−/−*^ iMEFs reconstituted with the indicated constructs. The top graph within each panel shows a representative experiment, and the bottom graph summarizes the mean values of three experiments performed on three independent sets of reconstituted cell lines. Each symbol in the top graph represents a single cell, and the number of scored cells was ≥200 per sample. The mean is indicated. See also [Figure S2](#mmc1){ref-type="supplementary-material"}D for representative immunofluorescent staining images.(D) Representative BrdU FACS plots showing levels of resection in NCS-treated *53bp1*^*−/−*^ iMEFs reconstituted with the indicated constructs.(E) Summary graph showing quantification of the BrdU FACS data represented in (D) for six experiments performed on three independent sets of reconstituted cell lines. Numbers above each bar indicate the fold mean BrdU intensity over WT, which was set to 1.Significance in (B), (C), and (E) was calculated using the Mann-Whitney U test, and error bars represent SD. ^∗∗^p ≤ 0.01 and ^∗∗∗∗^p ≤ 0.0001; ns, not significant. See also [Figure S4](#mmc1){ref-type="supplementary-material"}B.

To assess whether abrogation of SQ/TQ phosphorylation in the 53BP1^ΔPro^ and 53BP1^ΔRif1^ mutants interfered with Rif1 interaction and recruitment to DSBs, we reconstituted *53bp1*^*−/−*^ iMEFs with 53BP1^WT^ and 53BP1 phospho mutants ([Figure S2](#mmc1){ref-type="supplementary-material"}C), and monitored 53BP1 and Rif1 foci formation after irradiation. In agreement with the observation that N-terminal phosphorylation is dispensable for recruitment of 53BP1 to sites of DNA damage, 53BP1^28A^ ([@bib6]), 53BP1^ΔPro^ and 53BP1^ΔRif1^ foci were readily detectable following irradiation ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}D). However, Rif1 did not form IRIF in 53BP1^ΔPro^ and 53BP1^ΔRif1^-reconstituted cells ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}D), thus indicating that both phospho mutants cannot support Rif1 relocalization to DSBs.

We next tested whether the inability of 53BP1^ΔPro^ and 53BP1^ΔRif1^ to recruit Rif1 to sites of DNA damage translated into impaired DNA end resection inhibition. iMEFs reconstituted with Rif1 interaction-deficient 53BP1 mutants displayed the same increased levels of resection as cells lacking 53BP1 (EV transduced) or cells expressing a 53BP1 mutant defective in DSB-induced chromatin recruitment (53BP1^mUDR^) ([Figures 2](#fig2){ref-type="fig"}D and 2E). These experiments confirm that Rif1 is the major effector in the regulation of DNA end resection downstream 53BP1. Altogether, these results indicate that abrogation of phosphorylation at SQ/TQ sites T302 to S625 is sufficient to abolish Rif1 recruitment to DSBs and 53BP1-dependent DNA end protection.

To assess to what extent 53BP1-Rif1-mediated regulation of DNA end processing contributes to CSR, we reconstituted *53bp1*^*−/−*^ splenocytes with 53BP1^ΔPro^ and 53BP1^ΔRif1^ ([Figures 3](#fig3){ref-type="fig"}A--3C). Phosphomutant-expressing splenocyte cultures displayed the same proliferation capability as their WT counterpart ([Figure S4](#mmc1){ref-type="supplementary-material"}A). We first assessed 53BP1^ΔPro^ and 53BP1^ΔRif1^ proficiency to interact with Rif1 following DNA damage by co-immunoprecipitation analysis. In agreement with the inability to recruit Rif1 to IR-induced DSBs in MEFs ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}D), 53BP1^ΔPro^ and 53BP1^ΔRif1^ failed to co-immunoprecipitate Rif1 following IR in B cells ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Next, we assessed CSR efficiency *ex vivo* in response to stimulation conditions that induce class switching to different isotypes. We monitored switching to IgG1, IgG2b, and IgG3 because CSR to these isotypes is robust, and thus it ensures a large dynamic range and a more accurate detection of even subtle differences in CSR levels. Whereas CSR was abrogated to all tested isotypes in *53bp1*^*−/−*^ B cells transduced with EV or 53BP1^mUDR^, Rif1 interaction-deficient 53BP1 rescued CSR to a considerable extent under all stimulation conditions ([Figures 3](#fig3){ref-type="fig"}D--3F; mean values of 72%, 66%, and 65% of WT levels for IgG1, IgG2b, and IgG3, respectively, for 53BP1^ΔRif1^). Taken together, these results indicate that 53BP1-Rif1 DSB end protection plays a limited role in 53BP1's ability to support CSR.Figure 3DSB End Protection-Deficient B Lymphocytes Undergo Robust CSR(A--C) Representative WB analysis of *53bp1*^*−/−*^ B lymphocytes reconstituted with the indicated 53BP1 viral constructs and stimulated to induce CSR to IgG1 (A), IgG2b (B), or IgG3 (C). Asterisk indicates an aspecific band used for internal normalization of protein levels. Numbers underneath each lane indicate mean values from relative quantification of 53BP1 WT and mutant protein levels in reconstituted *53bp1*^*−/−*^ splenocytes cultures compared with endogenous protein in the *WT* B cell culture. Quantification summarizes WB analyses of three independently reconstituted cultures per stimulation condition.(D--F) Top: representative flow cytometry plots measuring CSR to IgG1 (D), IgG2b (E), and IgG3 (F) in primary cultures of 53BP1 construct-reconstituted *53bp1*^*−/−*^ B lymphocytes. Bottom: summary dot plot for three independent experiments. CSR efficiencies within each experiment were normalized to the CSR value of 53BP1^WT^-reconstituted cells, which was set to 100%.Significance was calculated using the Mann-Whitney U test, and error bars represent SD. ^∗^p ≤ 0.05 and ^∗∗^p ≤ 0.01.

53BP1-Dependent DSB Mobility Is Dispensable for CSR {#sec2.4}
---------------------------------------------------

53BP1 mediates the mobility of deprotected telomeres and DSBs ([@bib25], [@bib48]). This function contributes to telomere fusion following ablation of the shelterin component TRF2, and generation of radial chromosomes in BRCA1-deficient cells ([@bib25], [@bib48]), the other two well-established DNA repair transactions that depend on 53BP1. Alanine substitutions of an internal set of SQ/TQ motifs (53BP1^ΔMob^; [Figure 2](#fig2){ref-type="fig"}A) abrogate 53BP1-dependent DNA end mobility without affecting its ability to repress hyper-resection of deprotected telomeres ([@bib48]). In agreement with these data, 53BP1^ΔMob^ rescued Rif1 foci formation in irradiated *53bp1*^*−/−*^ iMEFs to WT levels ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}D) and was proficient in protecting DSBs against resection ([Figures 2](#fig2){ref-type="fig"}D and 2E).

Given the limited dependency of CSR on 53BP1 regulation of DNA end processing, we tested whether 53BP1-mediated DSB mobility contributed to CSR. To do so, we measured the CSR efficiency of *53bp1*^*−/−*^ splenocytes reconstituted with 53BP1^ΔMob^ mutant. 53BP1^ΔMob^ rescued CSR to WT levels ([Figures 4](#fig4){ref-type="fig"}A and 4B), thus indicating that inactivation of DNA mobility SQ/TQ sites did not affect 53BP1's ability to support CSR. We concluded that 53BP1-mediated DSB end mobility is dispensable for CSR. In this regard, CSR differs from the other DNA repair transactions that are dependent on 53BP1, fusion of deprotected telomeres and radial formation, which both require the DNA end mobility activity in addition to the inhibition of DNA end resection ([Figure 4](#fig4){ref-type="fig"}C).Figure 453BP1-Mediated DSB Mobility Is Dispensable for CSR(A) Top: representative flow cytometry plots measuring CSR to IgG1 in *WT* and *53bp1*^*−/−*^ splenocytes transduced with the indicated constructs. Bottom: summary dot plot for four independent experiments. CSR efficiencies within each experiment were normalized to the CSR value of 53BP1^WT^-reconstituted cells, which was set to 100%. Significance was calculated using the Mann-Whitney U test, and error bars represent SD. ^∗^p ≤ 0.05; ns, not significant.(B) Representative WB analysis of *53bp1*^*−/−*^ B lymphocytes reconstituted with the indicated 53BP1 viral constructs.(C) Schematic representation of a 53BP1 tetramer. The blue appendages represent the N-terminal intrinsically disordered regions of each monomer and contain the Pro and Mob sets of SQ/TQ motifs. The UDR and Tudor domains of the 53BP1 monomers assemble into two nucleosome-binding dimers that are represented as yellow pincers. The relative contributions played by the regulation of DNA end processing, DSB mobility, and higher order oligomerization activities to CSR are indicated in red.

Discussion {#sec3}
==========

Whereas CSR is predominantly dependent on NHEJ, the repetitive nature of the switch regions favors MMEJ-mediated intra-S recombination, and the ability of 53BP1-Rif1 to counteract DNA end processing is believed to contribute substantially to the severe CSR defects caused by deficiency in these DSB repair factors. Here, we showed that B lymphocytes devoid of 53BP1-Rif1-mediated DNA end protection can undergo robust class switching. Conversely, defects in higher order multimerization completely abolish 53BP1's ability to support CSR without having a major impact on its DNA end resection inhibitory function. Considering the near complete abrogation of CSR in 53BP1- and Rif1-deficient B cells ([@bib14], [@bib22], [@bib32], [@bib50], [@bib75]), the major implication of these findings is that 53BP1 and Rif1 contribute multiple functions to CSR, with the regulation of DNA end resection activity only marginally influencing the process. This would explain the surprising observation that inhibition of CtIP-mediated end resection only negligibly rescues the CSR defect in 53BP1 and Rif1-deficient B lymphocytes ([@bib7], [@bib22]).

Despite a partially defective association with damaged chromatin, 53BP1 OD mutants supported considerable Rif1 recruitment and inhibition of DNA end resection. These results are reminiscent of the behavior of OD-impaired 53BP1 at dysfunctional telomeres ([@bib47]). 53BP1^ΔOligo^ exhibited only a mild localization defect to deprotected telomere-induced foci (TIFs) but was fully proficient with regard to counteracting CtIP-mediated telomere resection ([@bib47]). These observations raise the possibility that an independent oligomerization module may compensate for mutations within the OD and support sufficient levels of 53BP1 recruitment to damaged sites to ensure repression of DNA end processing (DSBs or dysfunctional telomeres). Indeed, during the preparation of this paper, another study reported that binding of the dimerization-inducing protein DYNLL1 to the LC8 motif in 53BP1 promoted OD-independent oligomerization and chromatin association ([@bib2]). Given the milder chromatin recruitment defect of the 53BP1 LC8 mutant ([@bib2]), the OD is likely to play a key role in the stabilization of 53BP1 oligomers.

We have found that the OD provides a tetramerization interface, and efficient higher order 53BP1 multimerization is essential for CSR. A single mutation within the OD core that still supports dimerization of the OD module abolishes CSR. Interestingly, deletion of the OD had a minor effect on the end joining of deprotected telomeres that specifically concerned the longest multichromosome fusion events, which might be limited by a less efficient interaction of distally located telomeric ends ([@bib47]). These findings are in agreement with a model in which 53BP1 dimers represent the minimum nucleosome-binding unit to allow DNA damage-dependent recruitment and inhibition of DNA end resection, whereas tetramerization (and higher order assembly) provides a tethering activity to bridge and stabilize distally located DNA ends ([Figure 4](#fig4){ref-type="fig"}C), including AID-induced DSBs in donor and acceptor switch regions or spatially separated telomeric ends. Consistent with this idea, 53BP1 facilitates long-range DNA end joining during V(D)J recombination ([@bib24]). The combined contribution of DSB end protection and distal break tethering to CSR explains the increase in MMEJ-mediated intra-S region repair events in 53BP1-deficient B cells ([@bib63]).

CSR is a complex process that relies on the coordinated interplay of chromatin reorganization, transcription, programmed DNA damage, and DSB repair ([@bib15], [@bib51], [@bib82]). It is not at all surprising that specific factors could contribute multiple functions within the same or even different steps of the reaction. Indeed, additional *Igh* locus-specific functions have been described for 53BP1, including enforcement of orientation-specific joining of AID breaks and a structural role in the maintenance of the locus architecture ([@bib26], [@bib33], [@bib65]). The extent to which these functions contribute to CSR is currently unknown. However, these and our findings suggest that, in addition to preventing resection of AID-induced breaks via Rif1 and the shieldin complex, 53BP1 plays the key role of maintaining the *Igh* locus in a configuration "primed" for productive CSR events.

No additional role during CSR has been described for Rif1 so far. However, we recently performed a proteomic-based screen to identify Rif1 interactors in primary B lymphocytes undergoing CSR and identified several transcriptional regulators in addition to genome stability factors ([@bib20]). This raises the intriguing possibility that Rif1 might contribute to the transcriptional control of CSR. Such a hypothesis is in line with several studies supporting Rif1 role as a transcriptional regulator in yeast and mammals ([@bib18], [@bib19], [@bib40], [@bib43], [@bib45], [@bib46], [@bib68], [@bib69], [@bib72]) and represents an exciting new direction of investigation into the coordinated control of pre- and post-DSB phases of CSR.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rat anti-CD180 (RP/14)BD BiosciencesCat\# 552128, RRID: [AB_394343](nif-antibody:AB_394343){#intref0010}Goat anti-IgA-PESouthern BiotechCat\# 1040-09Mouse anti-CD40 Clone HM40-3BioLegendCat\# 102902, RRID:[AB_312945](nif-antibody:AB_312945){#intref0015}Rabbit anti-53BP1Novus BiologicalsCat\# NB100-304, RRID:[AB_10003037](nif-antibody:AB_10003037){#intref0020}Mouse anti-Flag M2Sigma-AldrichCat\# F3165, RRID: [AB_259529](nif-antibody:AB_259529){#intref0025}Mouse anti-Flag M2 (HRP conjugated)Sigma-AldrichCat\# A8592, RRID: [AB_439702](nif-antibody:AB_439702){#intref0030}Rabbit anti-Rif1[@bib22]N/ARabbit anti-TubulinAbcamCat\# ab4074 RRID:[AB_2288001](nif-antibody:AB_2288001){#intref0035}Rat anti-IgG1-APC Clone X56BD BiosciencesCat\# 550874, RRID: [AB_398470](nif-antibody:AB_398470){#intref0040}Rat anti-IgG3-BIOT Clone R40-82BD BiosciencesCat\# 553401, RRID: [AB_394838](nif-antibody:AB_394838){#intref0045}Rat anti-IgG2b-PE Clone RMG2b-1BioLegendCat\# 406707, RRID: [AB_2563380](nif-antibody:AB_2563380){#intref0050}Goat anti-rabbit Alexa546InvitrogenCat\# A-11035, RRID: [AB_2534093](nif-antibody:AB_2534093){#intref0055}Goat anti-mouse Alexa488InvitrogenCat\# A-11029, RRID: [AB_2534088](nif-antibody:AB_2534088){#intref0060}Mouse anti-BrdU APC antibody (Clone Bu20a)BioLegendCat\# 339808 RRID:[AB_10895898](nif-antibody:AB_10895898){#intref0065}Mouse anti-HA probe antibody (F-7)Santa CruzCat\# sc-7392 RRID:[AB_627809](nif-antibody:AB_627809){#intref0070}Rabbit anti-HA-tag (C29F4)Cell SignalingCat\# 3724S RRID:[AB_1549585](nif-antibody:AB_1549585){#intref0075}Mouse-anti-RPA2 (12F3.3)Novus BiologicalsCat\# NB100-158 RRID:[AB_2180491](nif-antibody:AB_2180491){#intref0080}normal mouse IgGSanta CruzCat\# sc-2025 RRID:[AB_737182](nif-antibody:AB_737182){#intref0085}**Bacterial and Virus Strains**E.coli BL21 Rosetta 2NovagenCat\# 71400**Chemicals, Peptides, and Recombinant Proteins**RPMI 1640Life TechnologiesCat\# 21875091HEPESLife TechnologiesCat\# 15630056Sodium PyruvateLife TechnologiesCat\# 11360039Antibiotic AntimycoticLife TechnologiesCat\# 15240062L-GlutamineLife TechnologiesCat\# 250300242-MercaptoethanolLife TechnologiesCat\# 21985023DMEMLife TechnologiesCat\# 41965062Penicillin-StreptomycinLife TechnologiesCat\# 15140122Express^TM^ mediumNovagenCat\# 71491AEBSF (4-(2-Aminoethyl)benzensulfonylfluorid)Carl RothCat\# A154cOmplete^TM^ protease inhibitorRocheCat\# 11697498001BenzonaseSigmaCat\# E1014-25KUSinapinic acidSigma-AldrichCat\# \#D7927Cyano-4-hydroxycinnamic acidSigma-AldrichCat\# \#C2020Rat anti-CD43 (Ly-48) MicrobeadsMiltenyi BiotecCat\# 130-049-801LPSSigma-AldrichCat\# L2630IL-4 (mouse recombinant)Sigma-AldrichCat\# I1020BAFF (human recombinant)PeproTechCat\# 310-13TGFβ-1 (mouse recombinant)R&D SystemsCat\# 7666-MB-005/CFPuromycin dihydrochlorideSigma-AldrichCat\# P8833RIPA bufferSigmaCat\# R0278Complete EDTA-free protease inhibitor cocktailRocheCat\# 11873580001CellTrace VioletThermofisherCat\# C34557ParaformaldehydeSigma-AldrichCat\# P6148Hoechst 33258ThermofisherCat\# H3569Neocarzinostatin (NCS)SigmaCat\# N916216% Formaldehyde Methanol-freeThermo scientificCat\# 28908Dynabeads Protein GThermoFisherCat\# 10004DFuGENE® HD Transfection ReagentPromegaCat\# E2312Igepal CA-630SigmaCat\# I8896Pierce Phosphatase Inhibitor Mini TabletsThermoFisherCat\# A32957Phenylmethylsulfonyl fluorideSigma-AldrichCat\# 10837091001Pepstatin AMerckCat\# P5318**Critical Commercial Assays**APC BrdU Flow KitBD BiosciencesCat\# 552598Neon Transfection System, 100 μl KitInvitrogenCat\# MPK10025Expand Long Template PCR SystemSigma-AldrichCat\# 11681834001NucleoSpin DNA Purification KitMacherey-NagelCat\# 740499TOPO TA Cloning KitInvitrogenCat\# 450641Luna® Universal One-Step RT-qPCR KitNEBCat\# E3005S**Deposited Data**Original scans and IF imagesThis paper; Mendeley Data<https://data.mendeley.com/datasets/n7jxbpddnf/draft?a=d8838dbd-c9e9-40d5-b467-0150330356a1>**Experimental Models: Cell Lines**Murine: CH12 (CH12F3) - WT, parental[@bib54]N/AMurine: *53bp1*^*−/−*^ CH12[@bib20]N/AMurine: *53bp1*^*Δ6*^ CH12This paperN/AMurine: *53bp1*^*−/−*^ iMEFs[@bib6]N/AMurine: *WT* iMEFs[@bib6]N/AHuman: BOSC23[@bib59]N/A**Experimental Models: Organisms/Strains**Mouse: *53bp1*^*−/−*^ (and derived splenocytes cultures)[@bib74]N/A**Oligonucleotides**53BP1^ΔBRCT^-3xHA construct cloningSee [Table S2](#mmc1){ref-type="supplementary-material"}N/A53BP1^ΔPRO^- & 53BP1^ΔMOB^-3xFlag construct cloningSee [Table S2](#mmc1){ref-type="supplementary-material"}N/ACRISPR-Cas9 gene targetingSee [Table S2](#mmc1){ref-type="supplementary-material"}N/ARPA ChIP-qPCRSee [Table S2](#mmc1){ref-type="supplementary-material"}N/AEnd resection assaySee [Table S2](#mmc1){ref-type="supplementary-material"}N/ASwitch junctional analysisSee [Table S2](#mmc1){ref-type="supplementary-material"}N/A**Recombinant DNA**Plasmid: pET21b+NovagenCat\# 69741Plasmid: pMAL-C2XAddgeneCat\# \#75286Plasmid: pMX-53BP1^ΔBRCT^-3xFlag[@bib6]N/APlasmid: pMX-53BP1^ΔOligo^-3xFlag[@bib76]N/APlasmid: pMX-53BP1^ΔCore^-3xFlagThis paperN/APlasmid: pMX-53BP1^D1256A^-3xFlag[@bib83]N/APlasmid: pMX-53BP1^mTudor^-3xFlag[@bib9]N/APlasmid: pMX-53BP1^28A^-3xFlag[@bib6]N/APlasmid: pMX-53BP1^ΔPro^-3xFlagThis paperN/APlasmid: pMX-53BP1^ΔRif1^-3xFlagThis paperN/APlasmid: pMX-53BP1^ΔMob^-3xFlag[@bib48]N/APlasmid: pMX-53BP1^mUDR^-3xFlag[@bib36]N/APlasmid: pMX-53BP1^ΔBRCT^-3xHAThis paperN/APlasmid: pX458AddgeneCat\# \#48138Plasmid: pX458-Cas9^D10A^This paperN/A**Software and Algorithms**BZ-H4A/Advanced Analysis SoftwareKeyenceN/ABZ-H4C/Hybrid Cell CountKeyenceN/ABZ-H4CM/Macro Cell CountKeyenceN/AImageJNIHN/A

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michela Di Virgilio (<michela.divirgilio@mdc-berlin.de>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

Sources of mouse models and cell lines used in the study are reported below and in the Key Resources Table.

### Mice strains {#sec4.3.1}

*53bp1*^*−/−*^ mice (B6;129-*Trp53bp1*^*tm1Jc*^/J) were previously described ([@bib74]). 6 to 20 weeks old animals were used for the study, and age-matched groups were employed within each experiment. Both male and female mice were used for the experiments. Mice were maintained in a specific pathogen-free (SPF) barrier facility under standardized conditions (20+/−2°C temperature; 55% ± 15% humidity) on a 12 h light/12 h dark cycle. All experiments were performed in compliance with EU Directive 2010/63/EU, and in agreement with protocols approved by Landesamt für Gesundheit und Soziales (LAGeSo, Berlin).

### Primary cell cultures {#sec4.3.2}

Splenocytes cultures from *53bp1*^*−/−*^ mice were grown in RPMI 1640 medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES (Life Technologies), 1 mM Sodium Pyruvate (Life Technologies), 1X Antibiotic Antimycotic (Life Technologies), 2 mM L-Glutamine (Life Technologies), and 1X 2-Mercaptoethanol (Life Technologies) at 37°C and 5% CO2 levels.

### Cell lines {#sec4.3.3}

The cell lines employed for this study are: CH12 (CH12F3, murine, ([@bib54])), *53bp1*^*−/−*^ (*Trp53bp1*^*−/−*^*)* CH12 (murine, ([@bib20])), *53bp1*^*Δ6*^ CH12 (murine, this paper), WT and *53bp1*^*−/−*^ iMEFs (murine, ([@bib6])), and BOSC23 (human, ([@bib59])). CH12 cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES, 1 mM Sodium Pyruvate, 1X Antibiotic Antimycotic, 2 mM L-Glutamine, and 1X 2-Mercaptoethanol at 37°C and 5% CO2 levels. iMEFs and BOSC23 cells were cultured in DMEM medium (Life Technologies) supplemented with 10% FBS, 2 mM L-Glutamine, and Penicillin-Streptomycin (Life Technologies) at 37°C and 5% CO2 levels.

Method Details {#sec4.4}
--------------

### Protein expression {#sec4.4.1}

The nucleotide-sequence encoding residues 1233-1288 of human 53BP1 (Uniprot [Q12888](uniprotkb:Q12888){#intref0100}) was amplified by PCR and cloned into a modified pET21b+ vector (Novagen \#69741) encoding N-terminal MBP, followed by a 24 amino acid long linker. Site-directed mutagenesis was used to introduce the indicated mutations. The plasmids were transformed into *E.coli* BL21 Rosetta 2 (Novagen) and cells were grown at 37°C in Express^TM^ medium (Novagen) until an optical density at a wavelength of 600 nm (OD~600~) of 0.9, when the temperature was switched to 18°C for overnight expression. Alternatively, protein was produced in LB medium by inducing protein expression at an OD~600~ of 0.4 with 1 mM IPTG and 4 h incubation at 37°C. Cells were harvested by centrifugation and cell pellets stored at −20°C until purification. Thawed cells were resuspended in 20 mM HEPES (or 20 mM Tris-HCl) pH 7.5, 150 mM NaCl, 1 mM DTT with AEBSF (4-(2-Aminoethyl)benzensulfonylfluorid) and cOmplete^TM^ protease inhibitor (Roche) and lysed with a fluidizer (Microfluidics). Cell lysates were centrifuged at 35,000 rpm for 45 min at 4°C. The filtered supernatant was then incubated with 25 U/ml Benzonase for 25 min at 4°C to reduce nucleic acid contaminations and subsequently applied to an equilibrated MBP affinity column (GE). The column was washed with 20 column volumes (CV) of resuspension buffer at 4°C. Protein was eluted with 10 CVs of 20 mM HEPES (or 20 mM Tris-HCl) pH 7.5, 150 mM NaCl, 1 mM DTT, 40 mM maltose. The eluted protein was concentrated to 20 mg/ml using 10 kDa cutoff Amicon spin filters, followed by size exclusion chromatography on a Superdex S200 in running buffer containing 20 mM HEPES (or 20 mM Tris-HCl) pH 7.5, 150 mM NaCl, 1 mM DTT. Pooled fractions were concentrated in 10 kDa cutoff Amicon spin filters and frozen in small aliquots. Protein size was verified using MALDI-TOF with a 4-point calibration standard and sinapinic acid or α-cyano-4-hydroxycinnamic acid as matrix.

### RALS analysis {#sec4.4.2}

RALS analysis was performed on an analytical Superdex S200 10/300 column in running buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT, using an ÄKTApurifier and an online Malvern Viscotek RALS system (VE 3580 RI detector and 270 Dual detector). All protein samples were diluted to 2 mg/ml concentration in running buffer. 50 μl of each sample was applied and run at a flowrate of 0.5 ml/min. Data was recorded with UNICORN and OmniSEC 5.00 software and analyzed in OmniSEC 5.00 software. MBP expressed from plasmid pMAL-C2X was used as a control. Molecular weight (MW) of MBP-OD: 49.5 kDa. The clear shift in the elution volume of MBP (MW: 42.5 kDa) and MBP-OD^ΔCore^ (MW: 48.6 kDa) in [Figure 1](#fig1){ref-type="fig"}B is likely caused by the more extended shape of MBP-OD^ΔCore^.

### Cell cultures and retroviral infection {#sec4.4.3}

B lymphocytes were isolated from mouse spleens using anti-CD43 MicroBeads (Miltenyi Biotec) and stimulated to undergo class switching with 25 μg/ml LPS (Sigma-Aldrich) and 5 ng/ml of mouse recombinant IL-4 (Sigma-Aldrich) for CSR to IgG1; 25 μg/ml LPS, 10 ng/ml BAFF (PeproTech) and 2 ng/ml TGFβ (R&D Systems) for CSR to IgG2b; or 25 μg/ml LPS for CSR to IgG3. Cultures were supplemented with 0.5 μg/ml RP105 (BD) under all stimulation conditions. CH12 cells ([@bib54]) were stimulated to undergo CSR to IgA by treatment with 0.5 μg/ml αCD40 (BioLegend), 5 ng/ml TGFβ and 5 ng/ml of mouse recombinant IL-4 for 48 h.

pMX-53BP1 retroviral vectors were generated by cloning the cDNA for human 53BP1^ΔBRCT^ (aa 1-1710) into a pMX-based vector with a C-terminal 3XFlag tag. 53BP1^ΔBRCT^ backbone was employed as WT and for mutagenesis purposes since its reduced size allows efficient retroviral packaging and infection of B cells, while functionally behaving as the full-length protein in CSR, radials formation, and fusion of deprotected telomeres ([@bib6], [@bib47]). The 53BP1 mutants employed in this study are: 53BP1^ΔOligo^ (Δ1231-1270, ([@bib76])), 53BP1^ΔCore^ (Δ1254-1258, this study), 53BP1^D1256A^ ([@bib83]), 53BP1^mTudor^ (D1521R, ([@bib9])), 53BP1^28A^ (S6A, S13A, S25A, S29A, S105A, S166A, S176A, S178A, T302A, S437A, S452A, S523A, T543A, S580A, S625A, S674A, T696A, S698A, S784A, S831A, T855A, S892A, S1068A, S1086A, S1104A, S1148A, T1171A, S1219A, ([@bib6])), 53BP1^ΔPro^ (S6A, S13A, S25A, S29A, S105A, S166A, S176A, S178A, T302A, S437A, S452A, S523A, T543A, S580A, S625A, this study), 53BP1^ΔRif1^ (T302A, S437A, S452A, S523A, T543A, S580A, S625A, this study), 53BP1^ΔMob^ (S674A, T696A, S698A, S784A, S831A, T855A, S892A, S1068A, S1086A, S1104A, S1148A, T1171A, S1219A, ([@bib48])), and 53BP1^mUDR^ (L1619A, ([@bib36])). 53BP1^ΔPro^ was generated by combining the sequence containing the first 15 mutated SQ/TQ to SA/TA sites from 53BP1^28A^ and the sequence containing the following 13 SQ/TQ sites from 53BP1^WT^ into pMX vector using a new SgrAI site introduced via silent mutations at nucleotides 1893 and1896 of human 53BP1 coding sequence. 53BP1^ΔMob^ was generated by combining the sequence containing the first 15 SQ/TQ sites from 53BP1^WT^ and the sequence containing the following 13 mutated SQ/TQ to SA/TA sites from 53BP1^28A^ into pMX vector using the same strategy employed for 53BP1^ΔPro^. Primers used for 53BP1^ΔPro^/53BP1^ΔMob^ cloning are listed in [Table S2](#mmc1){ref-type="supplementary-material"}. 53BP1^ΔRif1^ was generated by subcloning the sequence encompassing the first 8 SQ sites from pMX-53BP1^WT^ into pMX-53BP1^ΔPro^ using BsrGI cloning site. 3x haemagglutinin (3xHA) tag was cloned at the C terminus of 53BP1^ΔBRCT^ by two sequential PCR rounds using the primers listed in [Table S2](#mmc1){ref-type="supplementary-material"}.

Splenocytes infections were performed as it follows. The 293T derivative cell line BOSC23 ([@bib59]) was transfected with pCL-Eco and pMX-53BP1 retroviral vectors using FuGENE® HD Transfection Reagent (Promega) to generate viral particle-containing supernatants. B cells were transduced twice with the viral supernatant, one and two days after isolation, and CSR was assessed 96 h post-activation. To control for any difference in the expression of the transduced constructs within each reconstitution experiment, 53BP1 protein levels were routinely monitored by western blot analysis, as it has been previously described ([@bib6], [@bib12], [@bib22], [@bib36]). iMEFs were transduced as described for splenocytes above, with the exception that only one round of infection was employed one day after seeding, and 2 μg/ml Puromycin (Sigma-Aldrich) was added to the cultures 24 h after infection.

### Generation of 53BP1 oligo mutant expressing CH12 cell lines {#sec4.4.4}

CH12 clonal derivatives were generated via electroporation with gRNA pairs and nickase Cas9-based plasmid. Tandem U6 cassettes were cloned into a mutated version of pX458 expressing Cas9^D10A^. Single GFP-positive cells were sorted in 96-well plates and clones were allowed to grow for 12 days before expansion. Clones were validated at the level of genomic scar and protein expression. The sequences of the gRNAs employed in this study are listed in [Table S2](#mmc1){ref-type="supplementary-material"}. Controls for *53bp1*^*−/−*^ and 53BP1 oligo mutants-expressing clonal derivatives included both WT cultures and clones derived from targeting CH12 with random sequences not present in mouse genome. CH12 cell lines were activated for 48 h with αCD40, IL-4, and TGFβ to induce CSR to IgA.

### Western blot analysis and Co-IP assays {#sec4.4.5}

Western blot analysis of protein levels was performed on whole cell lysates prepared by lysis in RIPA buffer (Sigma) supplemented with Complete EDTA free proteinase inhibitors (Roche).

For co-immunoprecipitation of differentially tagged 53BP1 proteins, BOSC23 cells were co-transfected with equal amounts of pMX-53BP1^WT^-3xHA and pMX-53BP1-3xFlag (WT, ΔOligo, ΔCore, or D1256A) using FuGENE® HD Transfection Reagent. 36 hours post-transfection, cells were irradiated (20 Gy) and left to recover for 1 hour. Cells were lysed in lysis buffer (20 mM Tris HCl, 150 mM NaCl, 0.5% Igepal CA-630 (Sigma), 1.5 mM MgCl2) supplemented with Complete EDTA-free protease inhibitor cocktail, Pepstatin A (Merck), phenylmethylsulfonyl fluoride (PMSF) (Sigma), Pierce Phosphatase Inhibitors (ThermoFisher), and Benzonase (Sigma). Lysates were clarified by 15 min centrifugation at 13,000 rpm at 4°C, and incubated with magnetic beads (DynaBeads Protein G, Thermo Fisher) conjugated with anti-HA antibody (Santa Cruz) for 1 h at 4 C. Proteins were eluted by incubation in NuPAGE LDS sample buffer (Invitrogen) supplemented with 45 mM DTT for 10 min at 72°C.

For 53BP1-Rif1 co-immunoprecipitation analysis, *53bp1*^*−/−*^ splenocytes were activated with 25 μg/ml LPS, 5 ng/ml of mouse recombinant IL-4, and 0.5 μg/ml RP105, and infected with pMX-53BP1-3xFlag retroviral constructs as described above. At 96 h post-activation, cells were irradiated (20Gy) and left to recover for 1 hour. Cells were harvested, and washed two times with 1x PBS and one time with polyvinylpyrrolidone (PVP) buffer (20 mM HEPES, 1.2% PVP 40, Complete EDTA-free protease inhibitor cocktail, Pierce Phosphatase Inhibitors, 0.5 mM DTT, Pepstatin A, and PMSF). Cells were lysed in lysis buffer (10 mM Tris HCl, 100 mM NaCl, 0.05% Igepal CA-630, 1 mM MgCl2) supplemented with Complete EDTA-free protease inhibitor cocktail, Pierce Phosphatase Inhibitors, Pepstatin A, PMSF, and Benzonase. Lysates were clarified by 15 min centrifugation at 13,000 rpm at 4°C, and incubated with magnetic beads (DynaBeads Protein G, Thermo Fisher) conjugated with anti-Flag M2 antibody (Sigma-Aldrich) for 1 h at 4°C. Proteins were eluted by incubation in NuPAGE LDS sample buffer supplemented with 45 mM DTT for 10 min at 72°C.

The antibodies used for WB analysis are: anti-53BP1 (Novus Biological), anti-Flag M2 (HRP conjugated) (Sigma-Aldrich), anti-Rif1 ([@bib22]), anti-Tubulin (Abcam), and anti-HA (Cell Signaling).

The indicated MWs of 214 and 190 kDa in the anti-53BP1 blots refer to the endogenous full-length 53BP1 and the retrovirally expressed ΔBRCT proteins, respectively.

### Flow cytometry {#sec4.4.6}

For class switching assays, cell suspensions were stained with fluorochrome-conjugated anti-IgG1, anti-IgG3 (BD-Biosciences), anti-IgG2b (BioLegend), or anti-IgA (Southern Biotech). Samples were acquired on an LSRFortessa cell analyzer (BD-Biosciences). For cell proliferation analysis by cell tracking dye dilution, primary B cells were pulsed with 5 μM CellTrace Violet (Thermofisher) for 20 min at 37C.

### Immunofluorescence {#sec4.4.7}

iMEFs were grown on coverslips overnight. Cells were irradiated (10 Gy IR) and allowed to recover for 2 h. Upon fixation with 4% paraformaldehyde (Sigma-Aldrich) and permeabilization with 0.5% Triton X-100, cells were stained with mouse anti-Flag M2 (Sigma-Aldrich), and rabbit anti-Rif1 serum ([@bib22]) antibodies as primary antibodies, and with goat anti-rabbit Alexa546 and goat anti-mouse Alexa488 (Invitrogen) as secondary antibodies, alongside permeable nuclear dye (Hoechst dye 33258, ThermoFisher). Images were acquired using inverted LSM700 laser scanning confocal microscope (Zeiss) for the representative images in [Figures S2](#mmc1){ref-type="supplementary-material"}B and S2D, and with inverted fluorescence phase contrast microscope Keyence BZ-X800E (Keyence) for the automated foci quantification in [Figures 1](#fig1){ref-type="fig"}F, 1G, [2](#fig2){ref-type="fig"}B, and 2C.

### BrdU assay for DNA end resection {#sec4.4.8}

The BrdU assay for DNA end resection was performed as previously described ([@bib70]). Briefly, iMEFs were incubated with 30 μM BrdU for 24 h, followed by treatment with 200 ng/mL Neocarzinostatin (NCS) for 3 h (+NCS samples) or mock-treated (-NCS samples). Cells were trypsinized, washed with PBS, and fixed with 75% ethanol in PBS for 16 h at −20°C. Cells were washed with 0.1% Tween 20 in PBS following fixation and each subsequent incubation. Each sample was split into 2 aliquots, one of which was denatured using 2 N HCl for 45 min at 22°C in order to measure total BrdU incorporation. Blocking was performed in 5% fetal bovine serum (FBS) in PBS for 1 h at 22°C. BrdU exposed on single-stranded DNA (ssDNA) stretches as a consequence of DNA end resection was detected under native conditions by incubation with APC-conjugated anti-BrdU antibody (BioLegend) in PBS supplemented with 5% FBS for 1 h at 22°C. BrdU fluorescence intensity was acquired using the BD LSRFortessa flow cytometer (BD Biosciences). Resection levels in [Figures 1](#fig1){ref-type="fig"}J and [2](#fig2){ref-type="fig"}E were expressed as the mean BrdU intensity of native NCS-treated cells normalized to the mean BrdU intensity value of the same cells under denatured conditions.

### Rosa26 DNA end resection assay (Rosa26-ERA) {#sec4.4.9}

The end resection assay was performed as previously described ([@bib20]). Single guide RNAs targeting two sequences 2276 bp apart within the *ROSA26* locus (gDSB-1 and gDSB-2) were cloned independently into pX458 plasmid (gDSB-1/2). CH12 cells were electroporated with a 1:1 mix of gDSB-1 and gDSB-2 constructs using the Neon Transfection System (Thermo Fisher Scientific). 24h later, GFP-positive cells were sorted and pellets were frozen. Genomic DNA was extracted according to standard protocols and individual repair junctions were amplified using nested PCR reactions. PCR products were extracted from agarose gel and sequenced. Single guide RNAs and primers used for the end resection assay are listed in [Table S2](#mmc1){ref-type="supplementary-material"}.

### RPA-ChIP {#sec4.4.10}

ChIP-qPCR for RPA was performed as it follows. 20 million cells were counted and stimulated for 30 h with 0.5 μg/ml αCD40, 5 ng/ml TGFβ, and 5 ng/ml of mouse recombinant IL-4. Cells were fixed with 1% Formaldehyde (Thermo Scientific) at 37°C for 10 min followed by addition of 1/20 volume of 2.5 M glycine (dissolved in PBS pH 7.4). Fixed cells were washed two times with ice cold PBS, centrifuged and aliquoted. Cells were resuspended in 800 μL of RIPA buffer supplemented with Complete EDTA free proteinase inhibitor and sonication was performed with a Covaris S220 Focused Ultrasonicator (peak value 105, duty factor 5, cycle/burst 200 for 20 minutes). Each ChIP was performed using 50-60 μg of chromatin. Chromatin fragments were pre-cleaned by incubation with Dynabeads Protein G (Thermofisher) with rotation at 4°C for 1 h, and immunoprecipitated with antibody-bound Dynabeads. 10 μg antibodies specific for RPA2 (Novus Biologicals) or normal mouse IgG (Santa Cruz) were used for each sample. DNA was amplified using Luna® Universal One-Step RT-qPCR Kit (NEB) on a StepOnePlus qPCR machine (Thermofisher). Primers used for RPA-ChIP analysis ([@bib77]) are listed in [Table S2](#mmc1){ref-type="supplementary-material"}.

### Switch Junction Analysis {#sec4.4.11}

For Sμ-Sα junctional analysis in CH12, cells were stimulated for 48 h with 0.5 μg/ml αCD40, 5 ng/ml TGFβ and 5 ng/ml of mouse recombinant IL-4, and sorted for IgA^+^ cells. Genomic DNA was extracted from the sorted population, and Sμ-Sα junctions were amplified by Expand long template PCR system (Sigma Aldrich). PCR conditions were: 38 cycles of denaturation 94°C for 15″, annealing 60°C for 30′, and elongation 68°C for 30′ (plus 30′ at each following cycle). PCR products were run on agarose gels, and fragments corresponding to 350-1000 bp were extracted with NucleoSpin DNA Purification Kit (Macherey-Nagel), cloned using TOPO-TA cloning kit (Invitrogen), and sequenced using M13 forward and reverse universal primers. Primers used for switch junction analysis ([@bib44]) are listed in [Table S2](#mmc1){ref-type="supplementary-material"}.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

The statistical significance of differences between groups/datasets was determined by the Mann--Whitney U test for all data presented in this study. Error bars in [Figures 1](#fig1){ref-type="fig"}D, 1J, [2](#fig2){ref-type="fig"}E, [3](#fig3){ref-type="fig"}D--3F, [4](#fig4){ref-type="fig"}A, and [S3](#mmc1){ref-type="supplementary-material"}C represent SD. Statistical details of experiments can also be found in the figure legends. Western blots were quantified using ImageJ image processing program (NIH). For quantification of oligomutant versus WT 53BP1-3xFlag proteins in anti-HA immunoprecipitates in [Figure 1](#fig1){ref-type="fig"}C, the signal associated with 53BP1-3xFlag proteins was normalized against the levels of 53BP1^WT^-3xHA in each corresponding pull-down. For quantification of 53BP1 protein levels in the western blot analyses in [Figures 3](#fig3){ref-type="fig"}A--3C, and repeats, the signal associated to 53BP1 was normalized with that of a aspecific reference band present in all lanes. IR-induced foci quantification in [Figures 1](#fig1){ref-type="fig"}F, 1G, and [2](#fig2){ref-type="fig"}B, and 2C was performed using the BZ-H4A/Advanced Analysis Software, BZ-H4C/Hybrid Cell Count and BZ-H4CM/Macro Cell Count analysis applications (Keyence).

Data and Code Availability {#sec4.6}
--------------------------

Original imaging and western blot data used to generate any of the figure panels have been deposited at Mendeley: <https://data.mendeley.com/datasets/n7jxbpddnf/draft?a=d8838dbd-c9e9-40d5-b467-0150330356a1>

Supplemental Information {#app2}
========================

Document S1. Figures S1--S4 and Tables S1 and S2Document S2. Article plus Supplemental Information
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